Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

(2012) Allan Lipton et al.   EUROPEAN JOURNAL OF CANCER

Denosumab

(2011) Lesley J. Scott et al.   DRUGS

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival analysis of patients with femoral metastases

(2011) Andreas F. Mavrogenis et al.   JOURNAL OF SURGICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007)

(2010) Mette Nørgaard et al.   JOURNAL OF UROLOGY

Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy

(2010) Allan Lipton   SEMINARS IN ONCOLOGY

Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

(2008) Vincent Launay-Vacher et al.   BREAST CANCER RESEARCH AND TREATMENT